Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

SkyePharma PLC - Product Pipeline Review - 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 33 | Code: MRS - 18608

Global Markets Directs, SkyePharma PLC Product Pipeline Review 2014, provides an overview of the SkyePharma PLCs pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SkyePharma PLCs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


The report provides brief overview of SkyePharma PLC including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of SkyePharma PLCs human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the SkyePharma PLCs pipeline products

Reasons to buy

Evaluate SkyePharma PLCs strategic position with total access to detailed information on its product pipeline
Assess the growth potential of SkyePharma PLC in its therapy areas of focus
Identify new drug targets and therapeutic classes in the SkyePharma PLCs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of SkyePharma PLC and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of SkyePharma PLC
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of SkyePharma PLC and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table Of Content 

Table of Contents 2
List of Tables 3
List of Figures 3
SkyePharma PLC Snapshot 4
SkyePharma PLC Overview 4
Key Information 4
Key Facts 4
SkyePharma PLC- Research and Development Overview 5
Key Therapeutic Areas 5
SkyePharma PLC- Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products- Monotherapy 8
Pipeline Products- Combination Treatment Modalities 9
Pipeline Products- Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
SkyePharma PLC- Pipeline Products Glance 12
SkyePharma PLC- Late Stage Pipeline Products 12
Pre-Registration Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
SkyePharma PLC- Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
SkyePharma PLC- Drug Profiles 15
(fluticasone propionate + formoterol fumarate) 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SKP-2075 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
terbutaline sulphate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SkyePharma PLC- Pipeline Analysis 20
SkyePharma PLC- Pipeline Products by Target 20
SkyePharma PLC- Pipeline Products by Route of Administration 21
SkyePharma PLC- Pipeline Products by Molecule Type 22
SkyePharma PLC- Pipeline Products by Mechanism of Action 23
SkyePharma PLC- Recent Pipeline Updates 24
SkyePharma PLC- Company Statement 28
SkyePharma PLC- Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
SkyePharma PLC - Key Manufacturing Facilities 31

Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables

SkyePharma PLC, Key Information 4
SkyePharma PLC, Key Facts 4
SkyePharma PLC- Pipeline by Indication, 2014 6
SkyePharma PLC- Pipeline by Stage of Development, 2014 7
SkyePharma PLC- Monotherapy Products in Pipeline, 2014 8
SkyePharma PLC- Combination Treatment Modalities in Pipeline, 2014 9
SkyePharma PLC- Out-Licensed Products in Pipeline, 2014 10
SkyePharma PLC- Out-Licensed Products/ Combination Treatment Modalities, 2014 11
SkyePharma PLC- Pre-Registration, 2014 12
SkyePharma PLC- Phase III, 2014 13
SkyePharma PLC- Phase II, 2014 14
SkyePharma PLC- Pipeline by Target, 2014 20
SkyePharma PLC- Pipeline by Route of Administration, 2014 21
SkyePharma PLC- Pipeline by Molecule Type, 2014 22
SkyePharma PLC- Pipeline Products by Mechanism of Action, 2014 23
SkyePharma PLC- Recent Pipeline Updates, 2014 24
SkyePharma PLC, Subsidiaries 30
SkyePharma PLC, Key Manufacturing Facilities 31

List of Figures

SkyePharma PLC - Pipeline by Top 10 Indication, 2014 6
SkyePharma PLC - Pipeline by Stage of Development, 2014 7
SkyePharma PLC - Combination Treatment Modalities in Pipeline, 2014 9
SkyePharma PLC - Pipeline by Top 10 Target, 2014 20
SkyePharma PLC - Pipeline by Top 10 Route of Administration, 2014 21
SkyePharma PLC - Pipeline by Top 10 Molecule Type, 2014 22
SkyePharma PLC - Pipeline Products by Top 10 Mechanism of Action, 2014 23

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing